MorphoSys (MPSYF) 6-K MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2022

COMMISSION FILE NUMBER 001-38455

MorphoSys AG

Semmelweisstrasse 7

82152 Planegg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On August 3, 2022, MorphoSys AG (the “Company”) issued a press release with the second quarter and first half 2022 financial results attached hereto as Exhibit 99.1. On August 4, 2022, MorphoSys AG (the “Company”), held its Q2 2022 results conference call attached hereto as Exhibit 99.2.

Exhibits

99.1    MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

99.2    Q2 2022 Results & Business Update

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MORPHOSYS AG (Registrant)

Date: August 4, 2022    By:    /s/ i.A. Kristina Grötsch

        Name: Kristina Grötsch

        Title:    Senior Specialist Investor Relations    

    By:    /s/ i.A. Robert Mayer    

        Name: Dr. Robert Mayer

        Title:    Director Investor Relations